Scott J. Cotler

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Jérémie Guedj, Harel Dahari, Libin Rong et al. · Proceedings of the National Academy of Sciences · 2013 · 342 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Christopher Koh, Laëtitia Canini, Harel Dahari et al. · The Lancet Infectious Diseases · 2015 · 263 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?

Grace Guzman, Elizabeth M. Brunt, Lydia M. Petrovic et al. · PubMed · 2008 · 185 citations

Medicine, Oncology, Pathology +17

Does Nonalcoholic Fatty Liver Disease Predispose Patients to Hepatocellular Carcinoma in the Absence of Cirrhosis?

Grace Guzman, Elizabeth M. Brunt, Lydia M. Petrovic et al. · Archives of Pathology & Laboratory Medicine · 2008 · 178 citations

Medicine, Oncology, Pathology +17

Productive Replication of Hepatitis C Virus in Perihepatic Lymph Nodes In Vivo: Implications of HCV Lymphotropism

Sampa Pal, Daniel G. Sullivan, Sean Kim et al. · Gastroenterology · 2006 · 166 citations

Life Sciences, Immunology, Infectious Diseases +12